Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

Rhea-AI Summary

Genocea Biosciences (NASDAQ: GNCA) will hold its third quarter 2020 financial results and corporate update on October 29, 2020, at 8:30 a.m. EDT. Participants can join by calling (844) 826-0619 domestically or (315) 625-6883 internationally, using conference ID 5951388. A live webcast is available on the Genocea investor relations page. A replay will be accessible post-event for 90 days. Genocea aims to develop personalized cancer immunotherapies using its ATLAS™ platform to identify effective neoantigens.

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

 

FAQ

When is Genocea Biosciences' Q3 2020 earnings call?

Genocea Biosciences will host its Q3 2020 earnings call on October 29, 2020, at 8:30 a.m. EDT.

How can I access the Genocea Biosciences conference call?

You can access the conference call by dialing (844) 826-0619 for domestic callers or (315) 625-6883 for international callers, using conference ID 5951388.

Where can I find the webcast for Genocea's Q3 2020 update?

The live webcast can be accessed on the investor relations section of the Genocea website.

What are Genocea's main projects mentioned in the PR?

Genocea is advancing two key programs: GEN-009, a neoantigen vaccine, and GEN-011, a neoantigen-specific cell therapy.

How long will the Genocea earnings call replay be available?

The webcast replay of the earnings call will be available for 90 days starting approximately two hours after the event.